Biogen Inc.
Biogen Inc is a US-based biotechnology company focused on treatments for neurological and neurodegenerative conditions. Investors should know the company mixes mature revenue-generating drugs for multiple sclerosis and spinal muscular atrophy with a high-profile and sometimes volatile research pipeline. Biogen’s market capitalisation is around $21.44B, which reflects both its commercial products and the market’s view of future approvals and patent timelines. Key drivers include clinical trial results, regulatory decisions, patent expiries and partnerships; these events can move the share price substantially. There is also reputational and regulatory risk following past controversy over Alzheimer’s therapy approvals. Biogen may appeal to investors who want exposure to neuroscience-focused biotech, but suitability depends on risk tolerance, investment horizon and portfolio diversification. This is general educational information only and not personalised investment advice — consider seeking independent financial advice and review the company’s latest filings before making decisions.
Why It's Moving
Biogen beats Q3 earnings forecasts with pipeline momentum, but stock slides on analyst downgrade and royalty worries.
Biogen reported stronger-than-expected Q3 2025 results, fueled by robust new product launches like Lecanemab, signaling promising growth in neuroscience therapies amid a competitive biotech landscape. Yet shares dipped over 5% as HSBC downgraded the stock, citing risks from declining CD20 royalties and multiple sclerosis erosion that could overshadow pipeline advances.
- Q3 revenue grew 3% year-over-year, with new launches generating $257 million—a 67% surge—highlighting Biogen's ability to offset legacy declines through innovation.
- Positive updates on LEQEMBI subcutaneous formulation and long-term data for zorevunersen in Dravet syndrome bolster the neurology pipeline, with FDA path cleared for high-dose SPINRAZA resubmission.
- HSBC downgrade flags weakening CD20 collaboration royalties and growth uncertainties, pressuring investor confidence despite strong free cash flow and upcoming pipeline readouts.
Biogen beats Q3 earnings forecasts with pipeline momentum, but stock slides on analyst downgrade and royalty worries.
Biogen reported stronger-than-expected Q3 2025 results, fueled by robust new product launches like Lecanemab, signaling promising growth in neuroscience therapies amid a competitive biotech landscape. Yet shares dipped over 5% as HSBC downgraded the stock, citing risks from declining CD20 royalties and multiple sclerosis erosion that could overshadow pipeline advances.
- Q3 revenue grew 3% year-over-year, with new launches generating $257 million—a 67% surge—highlighting Biogen's ability to offset legacy declines through innovation.
- Positive updates on LEQEMBI subcutaneous formulation and long-term data for zorevunersen in Dravet syndrome bolster the neurology pipeline, with FDA path cleared for high-dose SPINRAZA resubmission.
- HSBC downgrade flags weakening CD20 collaboration royalties and growth uncertainties, pressuring investor confidence despite strong free cash flow and upcoming pipeline readouts.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Biogen's stock with a target price of $177.51, suggesting growth potential.
Financial Health
Biogen Inc. is performing well with strong revenue and profits, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BIIB
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketAt-Home Healthcare Stocks Explained | FDA Approval
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug simplifies treatment and reduces the need for hospital visits. This development highlights a broader trend toward at-home care, creating potential investment opportunities in companies that provide related medical devices and healthcare services.
Published: August 30, 2025
Explore BasketThe Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: August 3, 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketThe Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: July 27, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Revenue and Pipeline
Biogen balances established drug sales with pipeline candidates; revenues can provide stability while trial readouts drive outlook, though results may be unpredictable.
Regulatory Catalysts
Regulatory decisions and trial outcomes are key value drivers — positive news can boost sentiment, but setbacks can quickly reverse gains.
Industry Dynamics
Competition, patent lifecycles and pricing pressure shape long-term prospects; consider diversification and risk tolerance before exposure, as biotech can be volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
